Your browser doesn't support javascript.
loading
Intermittent PI3Kδ inhibition sustains anti-tumour immunity and curbs irAEs.
Eschweiler, Simon; Ramírez-Suástegui, Ciro; Li, Yingcong; King, Emma; Chudley, Lindsey; Thomas, Jaya; Wood, Oliver; von Witzleben, Adrian; Jeffrey, Danielle; McCann, Katy; Simon, Hayley; Mondal, Monalisa; Wang, Alice; Dicker, Martina; Lopez-Guadamillas, Elena; Chou, Ting-Fang; Dobbs, Nicola A; Essame, Louisa; Acton, Gary; Kelly, Fiona; Halbert, Gavin; Sacco, Joseph J; Schache, Andrew Graeme; Shaw, Richard; McCaul, James Anthony; Paterson, Claire; Davies, Joseph H; Brennan, Peter A; Singh, Rabindra P; Loadman, Paul M; Wilson, William; Hackshaw, Allan; Seumois, Gregory; Okkenhaug, Klaus; Thomas, Gareth J; Jones, Terry M; Ay, Ferhat; Friberg, Greg; Kronenberg, Mitchell; Vanhaesebroeck, Bart; Vijayanand, Pandurangan; Ottensmeier, Christian H.
Afiliação
  • Eschweiler S; La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Ramírez-Suástegui C; La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Li Y; La Jolla Institute for Immunology, La Jolla, CA, USA.
  • King E; Division of Biological Sciences, University of California San Diego, La Jolla, CA, USA.
  • Chudley L; CRUK and NIHR Experimental Cancer Medicine Center, University of Southampton, Southampton, UK.
  • Thomas J; Dorset Cancer Centre, Poole Hospital NHS Foundation Trust, Poole, UK.
  • Wood O; Liverpool Head and Neck Center and Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • von Witzleben A; CRUK and NIHR Experimental Cancer Medicine Center, University of Southampton, Southampton, UK.
  • Jeffrey D; CRUK and NIHR Experimental Cancer Medicine Center, University of Southampton, Southampton, UK.
  • McCann K; CRUK and NIHR Experimental Cancer Medicine Center, University of Southampton, Southampton, UK.
  • Simon H; Department of Otorhinolaryngology, Head and Neck Surgery, Ulm University Medical Center, Ulm, Germany.
  • Mondal M; CRUK and NIHR Experimental Cancer Medicine Center, University of Southampton, Southampton, UK.
  • Wang A; CRUK and NIHR Experimental Cancer Medicine Center, University of Southampton, Southampton, UK.
  • Dicker M; La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Lopez-Guadamillas E; La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Chou TF; La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Dobbs NA; La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Essame L; UCL Cancer Institute, University College London, London, UK.
  • Acton G; La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Kelly F; Centre for Drug Development, Cancer Research UK, London, UK.
  • Halbert G; Centre for Drug Development, Cancer Research UK, London, UK.
  • Sacco JJ; Centre for Drug Development, Cancer Research UK, London, UK.
  • Schache AG; Centre for Drug Development, Cancer Research UK, London, UK.
  • Shaw R; Cancer Research UK Formulation Unit, University of Strathclyde, Glasgow, UK.
  • McCaul JA; Liverpool Head and Neck Center and Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Paterson C; Clatterbridge Cancer Centre NHS Foundation Trust and Liverpool Cancer Research UK Experimental Cancer Medicine Center Liverpool, Liverpool, UK.
  • Davies JH; Liverpool Head and Neck Center and Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Brennan PA; Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Singh RP; Liverpool Head and Neck Center and Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
  • Loadman PM; Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
  • Wilson W; Queen Elizabeth University Hospital, Glasgow, UK.
  • Hackshaw A; Beatson West of Scotland Cancer Centre, Glasgow, UK.
  • Seumois G; Dorset Cancer Centre, Poole Hospital NHS Foundation Trust, Poole, UK.
  • Okkenhaug K; Queen Alexandra Hospital, Portsmouth, UK.
  • Thomas GJ; Southampton University Hospitals NHS Foundation Trust, Southampton, UK.
  • Jones TM; University of Bradford, Institute of Cancer Therapeutics, Bradford, UK.
  • Ay F; Cancer Research UK and UCL Cancer Trials Centre, London, UK.
  • Friberg G; Cancer Research UK and UCL Cancer Trials Centre, London, UK.
  • Kronenberg M; La Jolla Institute for Immunology, La Jolla, CA, USA.
  • Vanhaesebroeck B; Department of Pathology, University of Cambridge, Cambridge, UK.
  • Vijayanand P; CRUK and NIHR Experimental Cancer Medicine Center, University of Southampton, Southampton, UK.
  • Ottensmeier CH; Liverpool Head and Neck Center and Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK.
Nature ; 605(7911): 741-746, 2022 05.
Article em En | MEDLINE | ID: mdl-35508656
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Cabeça e Pescoço / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias de Cabeça e Pescoço / Antineoplásicos Tipo de estudo: Clinical_trials Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article